| Autor: |
Wu, Shuang, Li, Panpan, Zhang, Qingsong, Sun, Xiao, Cong, Binbin, Wang, Yongsheng |
| Zdroj: |
Future Oncology; May2024, Vol. 20 Issue 14, p951-958, 8p |
| Abstrakt: |
Purpose: To explore the clinical application value of indocyanine green (ICG)–rituximab in sentinel lymph node biopsy. Methods: This study included 156 patients with primary breast cancer: 50 patients were enrolled in dose-climbing test, and 106 patients were enrolled in verification test. This was to compare the consistency of ICG–rituximab and combined method in the detected lymph nodes. Results: According to the verification test, the imaging rate of ICG–rituximab was 97.3%. Compared with the combined method, the concordance rate of fluorescence method was 0.991 (28 + 78/107; p < 0.001). Conclusion: For ICG–rituximab as a fluorescent targeting tracer, the optimal imaging dose of ICG 93.75 μg/rituximab 375 μg can significantly reduce the imaging of secondary lymph nodes. Compared with the combined method, it has a higher concordance rate. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
